? Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ? ? Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ? SAN DIEGO, Feb. 11, 2026 /PRNewswire/ — QuidelOrtho…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
